Table 2.
Angiogenic genes altered in the context of EPHA2-silencing comparing infected with uninfected siEPHA2_I/siEPHA2_U for fold-changes of ≤0.5 and ≥1.5.
| FC 1 ≤ 0.5 | FC 1 ≥ 1.5 |
|---|---|
| Pro-Angiogenic | Pro-Angiogenic |
| EGF | CCL2/MCP-1 |
| HGF | CXCL8/IL8 |
| IGFBP1 | FGF7/KGF |
| IGFBP2 | HBEGF |
| IL1B/IL1F2 | PDGF-AA |
| NRG1B1/HRG1B1 | PLAU/uPA |
| PTX3/TSG14 | PRL |
| TYMP/PD-ECGF | VEGFA |
| Anti-angiogenic factors | |
| ADAMTSL1 | |
| TIMP1 | |
| TIMP4 | |
| SERPINF1 |
1 FC—Fold-Change. Abbreviations: ADAMTSL1 (ADAM metallopeptidase with thrombospondin type 1 motif 1), FGF7/KGF (fibroblast growth factor 7), IL1B (interleukin 1 beta), NRG1 (neuregulin 1 beta1), PRL (prolactin), PTX3 (pentraxin 3), TIMP1 (tissue inhibitor of metalloproteinases 1), TIMP4 (tissue inhibitor of metalloproteinase 4), and TYMP/PD-ECGF (platelet-derived endothelial cell growth factor). See Table 1 for other abbreviation names.